- Home
- MESO vs KBDC Comparison
MESO vs KBDC Comparison
Compare MESO & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- KBDC
- Stock Information
- Founded
- MESO 2004
- KBDC 2021
- Country
- MESO Australia
- KBDC United States
- Employees
- MESO N/A
- KBDC N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- KBDC
- Sector
- MESO Health Care
- KBDC
- Exchange
- MESO Nasdaq
- KBDC Nasdaq
- Market Cap
- MESO 1.2B
- KBDC 1.2B
- IPO Year
- MESO N/A
- KBDC N/A
- Fundamental
- Price
- MESO $14.63
- KBDC $16.67
- Analyst Decision
- MESO Strong Buy
- KBDC Buy
- Analyst Count
- MESO 4
- KBDC 5
- Target Price
- MESO $13.50
- KBDC $17.30
- AVG Volume (30 Days)
- MESO 552.8K
- KBDC 93.9K
- Earning Date
- MESO 08-28-2024
- KBDC 02-15-2025
- Dividend Yield
- MESO N/A
- KBDC 3.01%
- EPS Growth
- MESO N/A
- KBDC N/A
- EPS
- MESO N/A
- KBDC N/A
- Revenue
- MESO $5,902,000.00
- KBDC N/A
- Revenue This Year
- MESO $66.05
- KBDC $172.54
- Revenue Next Year
- MESO $348.27
- KBDC $14.28
- P/E Ratio
- MESO N/A
- KBDC N/A
- Revenue Growth
- MESO N/A
- KBDC N/A
- 52 Week Low
- MESO $1.61
- KBDC $15.69
- 52 Week High
- MESO $19.15
- KBDC $17.22
- Technical
- Relative Strength Index (RSI)
- MESO 64.37
- KBDC N/A
- Support Level
- MESO $12.20
- KBDC N/A
- Resistance Level
- MESO $19.15
- KBDC N/A
- Average True Range (ATR)
- MESO 0.98
- KBDC 0.00
- MACD
- MESO 0.37
- KBDC 0.00
- Stochastic Oscillator
- MESO 48.93
- KBDC 0.00
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.